|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|Beta (3Y Monthly)||0.71|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 31, 2017 - Apr 3, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.50|
Provectus (PVCT) today provided an update on the Company’s small molecule clinical development program for its investigational immuno-dermatology drug PH-10 for the treatments of psoriasis and atopic dermatitis. Pathways significantly improved by PH-10 use include published psoriasis transcriptomes and cellular responses mediated by IL-17, IL-22, and interferons. The Company has finished two toxicology-focused, non-clinical, single administration studies using carbon-14- (14C-) labeled rose bengal disodium (RB) to demonstrate lack of systemic uptake.
Provectus (PVCT) today announced that Ed Pershing, CPA, the Chairman of the Company’s board of directors, was recognized by the Haslam College of Business (HCB) at the University of Tennessee, Knoxville as HCB’s 2018 Outstanding Entrepreneur. Mr. Pershing also is Chief Executive Officer and co-founder of 35-year-old, privately-held, healthcare management consulting and accounting firm PYA, P.C. Ed Pershing (HCB, ’74) grew up in Alcoa, Tennessee, surrounded by a supportive family.
KNOXVILLE, TN, Nov. 05, 2018 -- Provectus (OTCQB: PVCT) today announced that the Company was granted orphan drug designation (ODD) by the U.S. Food and Drug Administration.
- Single-agent adverse effect profiles of PV-10 and Keytruda were maintained - 65% overall objective response rate with 9% complete response, via RECIST 1.1 KNOXVILLE,.
- Assessing adverse event and preliminary efficacy profiles of PV-10 as single-agent and in combination with immune checkpoint inhibition for treatment of liver metastases.
- First cohort of 6 patients enrolled and treated; currently recruiting patients into second cohort KNOXVILLE, TN, Oct. 23, 2018 -- Provectus (OTCQB: PVCT) today announced.
KNOXVILLE, TN, Sept. 18, 2018-- Provectus today announced that the United States Patent and Trademark Office has allowed the Company’ s patent application for the use of adoptive cell transfer of PV-10-induced ...
KNOXVILLE, TN, Sept. 11, 2018-- Provectus today announced that data from two ongoing clinical trials, single agent PV-10 and PV-10 in combination with checkpoint inhibition for the treatment of uveal melanoma ...